An update on the role of leukotrienes in asthma

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 1, 2010, Pages 60-66

  Hallstrand, Teal S ^a   Henderson, William R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Asthma; Exercise induced bronchoconstriction; Leukotriene; Pharmacogenetics; Remodeling; T cell

Indexed keywords

CORTICOSTEROID DERIVATIVE; ICOSANOID; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; SALMETEROL;

ADD ON THERAPY; ALLERGIC DISEASE; ASTHMA; BRONCHOSPASM; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SENSITIZATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AIRWAY REMODELING; ANIMALS; ASTHMA; DISEASE PROGRESSION; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; POLYMORPHISM, GENETIC;

EID: 75849135422     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833489c3     Document Type: Review

References (71)

1. Mandal AK, Jones PB, Bair AM, et al.. The nuclear membrane organization of leukotriene synthesis. Proc Natl Acad Sci U S A 2008; 105:20434-20439.
2. Ago H, Kanaoka Y, Irikura D, et al.. Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 2007; 448:609-612.
3. Martinez Molina D, Wetterholm A, Kohl A, et al.. Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 2007; 448:613-616.
4. Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR Jr. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003; 111:S18-S34; discussion S34-16.
5. Zarini S, Gijon MA, Ransome AE, et al.. Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proc Natl Acad Sci U S A 2009; 106:8296-8301.
6. Singer AG, Ghomashchi F, Le Calvez C, et al.. Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 2002; 277:48535-48549.
7. Triggiani M, Giannattasio G, Calabrese C, et al.. Lung mast cells are a source of secreted phospholipases A2. J Allergy Clin Immunol 2009; 124:558-565; 565.e551-565.e553.
8. Hallstrand TS, Chi EY, Singer AG, et al.. Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness. Am J Respir Crit Care Med 2007; 176:1072-1078.
9. HendersonWRJr, Chi EY, Bollinger JG, et al.. Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med 2007; 204:865-877.
10. Munoz NM, Meliton AY, Arm JP, et al.. Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice. J Immunol 2007; 179:4800-4807.
11. Zhu J, Qiu YS, Figueroa DJ, et al.. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 2005; 33:531-540.
12. Beller TC, Maekawa A, Friend DS, et al.. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004; 279:46129-46134.
13. Uzonyi B, Lotzer K, Jahn S, et al.. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci U S A 2006; 103:6326-6331.
14. Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009; 124:406-414; quiz 415-416.
15. Gauvreau GM, Parameswaran KN, Watson RM, O'Byrne PM. Inhaled leukotriene E4, but not leukotriene D4, increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med 2001; 164:1495-1500.
16. Maekawa A, Kanaoka Y, Xing W, Austen KF. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 2008; 105:16695-16700.
17. Paruchuri S, Tashimo H, Feng C, et al.. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206: 2543-2555.
18. Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009; 124:422-427.
19. Drazen JM, Yandava CN, Dube L, et al.. Pharmacogenetic association between ALOX5 promoter genotype and the response to antiasthma treatment. Nat Genet 1999; 22:168-170.
20. Telleria JJ, Blanco-Quiros A, Varillas D, et al.. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102:857-861.
21. Lima JJ, Zhang S, Grant A, et al.. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173:379-385.
22. Tantisira KG, Lima J, Sylvia J, et al.. 5-lipoxygenase pharmacogenetics in asthma: overlap with cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 2009; 19:244-247.
23. Mougey EB, Feng H, Castro M, et al.. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19:129-138.
24. Yokomizo T, Kato K, Terawaki K, et al.. A second leukotriene B4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192:421-432.
25. Yokomizo T, Izumi T, Chang K, et al.. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387:620-624.
26. Watanabe S, Yamasaki A, Hashimoto K, et al.. Expression of functional leukotriene B4 receptors on human airway smooth muscle cells. J Allergy Clin Immunol 2009; 124:59-65; e51-e53.
27. Okuno T, Iizuka Y, Okazaki H, et al.. 12(S)-Hydroxyheptadeca-5Z, 8E, 10Etrienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 2008; 205:759-766.
28. Yokomizo T, Kato K, Hagiya H, et al.. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 2001; 276: 12454-12459.
29. Evans DJ, Barnes PJ, Spaethe SM, et al.. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 51:1178-1184.
30. Tager AM, Bromley SK, Medoff BD, et al.. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003; 4:982-990.
31. Medoff BD, Tager AM, Jackobek R, et al.. Antibody-antigen interaction in the airway drives early granulocyte recruitment through BLT1. Am J Physiol Lung Cell Mol Physiol 2006; 290:L170-L178.
32. Miyahara N, Takeda K, Miyahara S, et al.. Requirement for leukotriene B4 receptor 1 in allergen-induced airway hyperresponsiveness. Am J Respir Crit Care Med 2005; 172:161-167.
33. Terawaki K, Yokomizo T, Nagase T, et al.. Absence of leukotriene B4 receptor 1 confers resistance to airway hyperresponsiveness and Th2-type immune responses. J Immunol 2005; 175:4217-4225.
34. Miyahara N, Takeda K, Miyahara S, et al.. Leukotriene B4 receptor-1 is essential for allergen-mediated recruitment of CD8+ T cells and airway hyperresponsiveness. J Immunol 2005; 174:4979-4984.
35. Lundeen KA, Sun B, Karlsson L, Fourie AM. Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J Immunol 2006; 177:3439-3447.
36. Taube C, Miyahara N, Ott V, et al.. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006; 176:3157-3164.
37. Ohnishi H, Miyahara N, Dakhama A, et al.. Corticosteroids enhance CD8+ T cell-mediated airway hyperresponsiveness and allergic inflammation by upregulating leukotriene B4 receptor 1. J Allergy Clin Immunol 2008; 121:864- 871; e864.
38. Van Rensen EL, Sont JK, Evertse CE, et al.. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am J Respir Crit Care Med 2005; 172:837-841.
39. Islam SA, Thomas SY, Hess C, et al.. The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. Blood 2006; 107:444-453.
40. Cho KJ, Seo JM, Shin Y, et al.. Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low-affinity leukotriene B4 receptor. Am J Respir Cell Mol Biol 2009 [Epub ahead of print]. doi:10.1165/rcmb.2008- 0445OC.
41. Choi JA, Kim EY, Song H, et al.. Reactive oxygen species are generated through a BLT2-linked cascade in Ras-transformed cells. Free Radic Biol Med 2008; 44:624-634.
42. Lex C, Zacharasiewicz A, Payne DN, et al.. Exhaled breath condensate cysteinyl leukotrienes and airway remodeling in childhood asthma: a pilot study. Respir Res 2006; 7:63.
43. Henderson WR Jr, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173:718-728.
44. Suzuki S, Takeuchi K, Ishinaga H, et al.. Leukotriene D4 upregulates MUC2 gene transcription in human epithelial cells. Pharmacology 2008; 81:221-228.
45. Bai CH, Song SY, Kim YD. The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4-induced MUC2/5AC gene expression and mucin secretion in human airway epithelial cells. Auris Nasus Larynx 2007; 34:203-206.
46. Bosse Y, Thompson C, McMahon S, et al.. Leukotriene D4-induced, epithelial cell-derived transforming growth factor b1 in human bronchial smooth muscle cell proliferation. Clin Exp Allergy 2008; 38:113-121.
47. Parameswaran K, Radford K, Fanat A, et al.. Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines. Am J Respir Cell Mol Biol 2007; 37:240-247.
48. Altraja S, Kadai M, Rekker E, Altraja A. Synthesis of tenascin and laminin b2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. Respir Res 2008; 9:44.
49. Ichiyama T, Kajimoto M, Hasegawa M, et al.. Cysteinyl leukotrienes enhance tumour necrosis factor-a-induced matrix metalloproteinase-9 in human monocytes/ macrophages. Clin Exp Allergy 2007; 37:608-614.
50. Cabral AL, Conceicao GM, Fonseca-Guedes CH, Martins MA. Exerciseinduced bronchospasm in children: effects of asthma severity. Am J Respir Crit Care Med 1999; 159:1819-1823.
51. Hallstrand TS, Moody MW, Aitken ML, Henderson WR Jr. Airway immunopathology of asthma with exercise-induced bronchoconstriction. J Allergy Clin Immunol 2005; 116:586-593.
52. Carraro S, Corradi M, Zanconato S, et al.. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J Allergy Clin Immunol 2005; 115:764-770.
53. Hallstrand TS, Moody MW, Wurfel MM, et al.. Inflammatory basis of exerciseinduced bronchoconstriction. Am J Respir Crit Care Med 2005; 172:679-686.
54. Mickleborough TD, Lindley MR, Ray S. Dietary salt, airway inflammation, and diffusion capacity in exercise-induced asthma. Med Sci Sports Exerc 2005; 37:904-914.
55. Freed AN, McCulloch S, Meyers T, Suzuki R. Neurokinins modulate hyperventilation- induced bronchoconstriction in canine peripheral airways. Am J Respir Crit Care Med 2003; 167:1102-1108.
56. Lai YL, Lee SP. Mediators in hyperpnea-induced bronchoconstriction of guinea pigs. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:597-602.
57. Taylor-Clark TE, Nassenstein C, Undem BJ. Leukotriene D4 increases the excitability of capsaicin-sensitive nasal sensory nerves to electrical and chemical stimuli. Br J Pharmacol 2008; 154:1359-1368.
58. Hallstrand TS, Debley JS, Farin FM, Henderson WR Jr. Role of MUC5AC in the pathogenesis of exercise-induced bronchoconstriction. J Allergy Clin Immunol 2007; 119:1092-1098.
59. Hallstrand TS, Henderson WR Jr. Role of leukotrienes in exercise-induced bronchoconstriction. Curr Allergy Asthma Rep 2009; 9:18-25.
60. Pearlman DS, Van Adelsberg J, Philip G, et al.. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006; 97:98-104.
61. Philip G, Villaran C, Pearlman DS, et al.. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44:213-217.
62. Peroni DG, Piacentini GL, Ress M, et al.. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol 2002; 13:434-437.
63. Coreno A, Skowronski M, West E, et al.. Bronchoprotective effects of single doses of salmeterol combined with montelukast in thermally induced bronchospasm. Chest 2005; 127:1572-1578.
64. Stelmach I, Grzelewski T, Majak P, et al.. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 2008; 121:383-389.
65. Deykin A, Wechsler ME, Boushey HA, et al.. Combination therapy with a longacting b-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med 2007; 175:228-234.
66. Joos S, Miksch A, Szecsenyi J, et al.. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008; 63:453-462.
67. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol 2008; 121:1365-1371.
68. Lazarus SC, Chinchilli VM, Rollings NJ, et al.. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175:783-790.
69. Peters-Golden M, Swern A, Bird SS, et al.. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27:495-503.
70. Sarkar M, Koren G, Kalra S, et al.. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009. [Epub ahead of print]. DOI 10.1007/s00228-009-0713-9.
71. Bakhireva LN, Jones KL, Schatz M, et al.. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007; 119:618-625.